Functional Versatility of the CDK Inhibitor p57<sup>Kip2</sup>

Justine Creff and Arnaud Besson*

Centre National de la Recherche Scientifique, Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération, Centre de Biologie Intégrative, Université de Toulouse, Toulouse, France

The cyclin/CDK inhibitor p57<sup>Kip2</sup> belongs to the Cip/Kip family, with p21<sup>Cip1</sup> and p27<sup>Kip1</sup>, and is the least studied member of the family. Unlike the other family members, p57<sup>Kip2</sup> has a unique role during embryogenesis and is the only CDK inhibitor required for embryonic development. p57<sup>Kip2</sup> is encoded by the imprinted gene CDKN1C, which is the gene most frequently silenced or mutated in the genetic disorder Beckwith–Wiedemann syndrome (BWS), characterized by multiple developmental anomalies. Although initially identified as a cell cycle inhibitor based on its homology to other Cip/Kip family proteins, multiple novel functions have been ascribed to p57<sup>Kip2</sup> in recent years that participate in the control of various cellular processes, including apoptosis, migration and transcription. Here, we will review our current knowledge on p57<sup>Kip2</sup> structure, regulation, and its diverse functions during development and homeostasis, as well as its potential implication in the development of various pathologies, including cancer.

**Keywords:** p57<sup>Kip2</sup>, CDK inhibitor, cell cycle, development, transcription, stem cells, CDKN1C

INTRODUCTION

The cell division cycle is the fundamental process by which a cell duplicates its cytoplasmic and nuclear contents and divides in two genetically identical daughter cells. Cell cycle progression is driven by specific combinations of heterodimeric cyclin/CDK (cyclin-dependent kinase) complexes that license progression from one cell cycle phase to the next. In these complexes, the CDK is the catalytic subunit that has serine/threonine kinase activity and the cyclin subunit allows CDK activation and determines substrate specificity (Malumbres and Barbacid, 2005; Suryadinata et al., 2010). These actors are finely regulated at the level of transcription, localization, post-translational modifications (mainly phosphorylation) and protein degradation. Another level of regulation is their association with inhibitory partners called CKIs (Cyclin-dependent Kinase Inhibitor). CKIs are divided in two families according to their structure, CDK binding specificity and evolutionary origin: the INK4 family and the Cip/Kip family (Sherr and Roberts, 1999; Besson et al., 2008; Suryadinata et al., 2010).

The INK4 family (Inhibitors of CDK4) is composed of four proteins, p16<sup>INK4A</sup>, p15<sup>INK4B</sup>, p18<sup>INK4C</sup>, and p19<sup>INK4D</sup>, that specifically bind to CDK4 and CDK6 and inhibit their interaction with D-type cyclins, thus preventing their activation (Sherr and Roberts, 1999; Besson et al., 2008). In contrast, members of the Cip/Kip family, p21<sup>Cip1/Waf1</sup> (p21) (Harper et al., 1993), p27<sup>Kip1</sup> (p27) (Pollyak et al., 1994; Toyoshima and Hunter, 1994) and p57<sup>Kip2</sup> (p57) (Lee et al., 1995; Matsuoka et al., 1995) bind to both CDK and cyclin subunits and have the ability to inhibit all cyclin/CDK complexes (Sherr and Roberts, 1999; Besson et al., 2008). Cip/Kip proteins share a conserved
cyclin/CDK interaction domain in their N-terminal part, but diverge in their C-termini, suggesting that they play specific roles (Yoon et al., 2012). By inhibiting CDK activity, CKIs block proliferation and they are considered as tumor suppressor.

More recently, the characterization of the CKI interaction networks indicates that Cip/Kip family members plays multiple functions in the cell and that their roles are not restricted to cell cycle control but also extends to the regulation of other cellular processes (Besson et al., 2008).

In this review, we focus on the least studied Cip/Kip family member, p57, and give an overview of its regulation, multiple functions in physiology and implication in pathology.

**THE CDKN1C GENE**

p57 is encoded by **CDKN1C**, located in the telomeric region of chromosome 11 at 11p15.5 in human (Matsuoka et al., 1995), and in the distal region of chromosome 7 in mice (Hatada and Mukai, 1995). **CDKN1C** contains four exons and three introns and p57 is encoded only from exons 2 and 3 (Tokino et al., 1996).

**CDKN1C** is a paternally imprinted gene, with preferential expression from the maternal allele (Matsuoka et al., 1996). The 11p15.5 locus contains a cluster of genes submitted to genomic imprinting. Parental or genomic imprinting is a process required for normal embryonic development that involves epigenetic modifications of a gene causing its monoallelic expression in a parental-dependent manner (Monk et al., 2019). Imprinted genes are commonly found in clusters, which contain imprinting control regions (ICRs) that are enriched in CpG islands and are differentially methylated on each allele. These regions also often include non-coding antisense RNAs that are essential for maintaining imprinting (Reik and Walter, 2001). Interestingly, the region homologous to 11p15.5 on murine chromosome 7 has the same gene cluster arrangement, highlighting the importance of this organization for the regulation of these genes. This locus covers about 1 Mb and is organized in two domains controlled by two regulatory centers, ICR1 and ICR2 (Figure 1).

ICR1 in the telomeric domain controls the reciprocal expression of **H19** (maternal expression) and **IGF2** (paternal expression). The expression of these two genes depends on the same pair of enhancers whose access is regulated by ICR1 (Leighton et al., 1995). On the paternal allele, unmethylated ICR1 is bound by CTCF (CCCTC-binding factor), a zinc-finger protein with insulating activity, preventing the interaction of the enhancers with the **IGF2** promoter, but allowing activation of the **H19** promoter, which is expressed. Conversely, on the paternal allele, CTCF does not recognize the methylated ICR1, allowing the interaction of the enhancers with the **IGF2** promoter and its expression, while **H19** is repressed (Hark et al., 2000; Eggermann et al., 2014b).

The centromeric domain is approximately 800 kb in size and contains several ubiquitously imprinted genes, including **KCNQ1**, **KCNQ1OT1** (**KCNQ1 Opposite strand/antisense transcript 1**, a.k.a. **LIT1** [Long QT intron transcript 1]), **CDKN1C**, **SLC22A18**, and **PHLDA2**, whose expression is regulated by ICR2. ICR2, located in intron 10 of **KCNQ1** corresponding to the **KCNQ1OT1** promoter, is methylated on the maternal allele, which represses **KCNQ1OT1** expression and thereby allows maternal expression of all the other genes of the domain. Conversely, ICR2 is unmethylated on the paternal allele, allowing **KCNQ1OT1** expression. **KCNQ1OT1** is a non-coding antisense RNA that represses in cis the other genes of the domain (Fitzpatrick et al., 2002; Eggermann et al., 2014b) (Figure 1). **KCNQ1OT1** directly binds to chromatin at the promoters of the imprinted genes and recruits histone methyltransferase complexes such as EZH2 (Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit) and EHM2 (Euchromatic Histone Lysine Methyltransferase 2), resulting in a repressive chromatin state (Pandey et al., 2008). In addition, **KCNQ1OT1** recruits DNMT1 (DNA methyltransferase 1) to these promoters, causing their hypermethylation and reinforcing paternal repression (Mohammad et al., 2010). Imprinting defects in this locus are one of the most frequent cause of development of several syndromes (see below). Some genes in this locus are imprinted only in the placenta in mice (**Ascl2**, **CD81**, and **Tsc2**) (Shmela and Gicquel, 2013).

**REGULATION OF CDKN1C EXPRESSION**

p57 expression is finely regulated by many signals and transcription factors. **CDKN1C** promoter analysis revealed the presence of several consensus sites for various transcription factors, including several SP1 (Stimulatory protein-1) sites, a Glucocorticoid response element (GRE) site, and a TATA box. The transcription factors E47, E2F1 and EGR1 (Early growth response gene 1), Tcf4, Hif1-α, as well as MyoD, via a p73 dependent mechanism, all promote p57 expression (Samuelsson et al., 1999; Rothschild et al., 2006; Vaccarello et al., 2006; Ma and Cress, 2007; Roeb et al., 2007; Wierenga et al., 2014). Stimulation with glucocorticoids or BMPs also induce p57 expression (Samuelsson et al., 1999; Gossellet et al., 2007; Shi and Liu, 2011; Zhang et al., 2015). Conversely, p57 transcription is repressed by the Notch effectors Hes1 and Herp2, as well as Id2 and PAX3-FOX01 (Rothschild et al., 2006; Jia et al., 2007; Roeb et al., 2007; Riccio et al., 2008). TGF-β signals have antagonistic roles depending on cell type. Indeed, the TGF-β/Smad pathway stimulates p57 expression in hematopoietic stem cells, whereas it induces its degradation in osteoblasts (Urano et al., 1999; Scandura et al., 2004). The **CDKN1C** promoter is strongly regulated by methylation on the numerous CpG islands located upstream and downstream of the transcription start site, which appears to play a critical role in mediating p57 silencing in cancers (see below).

In carcinomas, multiple micro-RNAs have been shown to repress p57 expression. For example, p57 is targeted by miR221/222 in gastric, lung and hepatocellular cancers, promoting cell proliferation and tumor growth (Fornari et al., 2008; Kim et al., 2009; Wang et al., 2013). Similarly, p57 expression is down-regulated by miR25 in glioma and gastric cancer (Kim et al., 2009; Zhang et al., 2015) and by miR21 in prostate cancer (Mishra et al., 2014). In the context of stem cells, p57 is regulated by miR92. In human embryonic stem cells, miR92-b targets p57, promoting G1/S transition and
Imprinting control of the 11p15.5 locus. The 11p15.5 locus is organized in two domains, telomeric and centromeric, each controlled by an imprinting control region (ICR). Imprinting of the telomeric region is controlled by ICR1, which allows repression of H19 and expression of IGF2 on the paternal allele, and reciprocal expression on the maternal allele. ICR2 controls imprinting of the centromeric domain. Methylation of ICR2 leads to the suppression of the LIT1 antisense RNA of the KCNQ1OT1 locus, allowing the expression of p57 from the maternal allele.

FIGURE 1 | Imprinting control of the 11p15.5 locus. The 11p15.5 locus is organized in two domains, telomeric and centromeric, each controlled by an imprinting control region (ICR). Imprinting of the telomeric region is controlled by ICR1, which allows repression of H19 and expression of IGF2 on the paternal allele, and reciprocal expression on the maternal allele. ICR2 controls imprinting of the centromeric domain. Methylation of ICR2 leads to the suppression of the LIT1 antisense RNA of the KCNQ1OT1 locus, allowing the expression of p57 from the maternal allele.

Over the past few years, RNA modifications were shown to play an important role in RNA stability and translation and it appears that aberrant modifications are involved in tumorigenesis (Chen et al., 2019). NSUN2 (NOP2/Sun RNA methyltransferase 2), the main enzyme catalyzing 5-methylcytosine (m5C) formation, is upregulated in gastric cancer and promote cell proliferation and tumorigenesis via m5C methylation of the p57 mRNA, repressing p57 expression (Mei et al., 2020).

Unlike other Cip/Kip family members, p57 exhibits a tissue-specific expression pattern with marked variations of expression from embryogenesis to adulthood. During embryogenesis, p57 is strongly expressed from E9.5 to birth, with peak expression at key stages of differentiation in each organ. p57 is present in all three embryonic germ layers (endoderm, mesoderm, and ectoderm), and is found in the majority of organs: cartilage, skeletal muscle, heart, nervous system, and parenchymal organs (intestine, pancreas, lungs, adrenals, thymus, gonad, and kidney) as well as in extra-embryonic tissues. After E13.5, its expression strongly decreases in most tissues, but persists in skeletal muscle, kidney, intestine, palate, and lens (Nagahama et al., 2001; Westbury et al., 2001). In adults, p57 is expressed in post-mitotic cells of a limited number of tissues (heart, brain, lungs, skeletal muscle, placenta, kidney, gonads, intestine, and more weakly in the liver and spleen), which distinguishes it from the ubiquitous expression of p27 and p21 (Lee et al., 1995; Matsuoka et al., 1995).

p57 STRUCTURE AND REGULATION

p57<sup>Kip2</sup> is a protein of 316 amino acids in human and 335 in mice, with an apparent molecular weight of 57 kDa. The murine p57 protein is organized into four domains (Figure 2): domain I comprises the cyclin/CDK binding domain and has high homology to p21 and p27. Domain II is a Proline-rich region of 82 amino acids, followed by domain III of 107 amino
FIGURE 2 | Structure of the p57Kip2 protein. Cip/Kip proteins are highly conserved in their N-terminal domain that mediates binding to cyclins and CDKs, but diverge in their C-terminal part. Nevertheless, the C-terminus of p57 presents some homology with p21 (PCNA binding domain) and p27 (QT motif). Murine and human p57 are conserved in their N- and C-terminal domains but the central domains (II and III) in mice are substituted by a unique PAPA domain in human (II). The N-terminal CDK binding/inhibitory domain (KID) of p57 is subdivided in three domains: a cyclin binding domain (1), a CDK binding domain (2) and a 310 helix (3). The C-terminal QT domain (238–316) of p57 presents strong homology to the p27 QT motif at amino acids 302–316. It also contains three other conserved motifs: a PCNA binding domain (272–297), a nuclear localization signal (NLS, 278–281), and a CDK phosphorylation site (T310). Through its diverse domains p57 is able to interact with multiple partners involved in numerous cellular process, such as MyoD, b-Myb, LIMK1, PCNA, or JNK.

acids rich in acidic residues (glutamic and aspartic acids). Finally, domain IV comprises a conserved motif called the QT domain presenting homology with p27 (QT motif) and p21 (PCNA binding domain). Human p57 is conserved in the C- and N-terminal parts, however, the central domains II and III are replaced by a single distinct domain rich in Proline/Alanine repeats, the PAPA domain (Figure 2) (Lee et al., 1995; Matsuoka et al., 1995). It is important to note that, like other Cip/Kip family proteins, p57 is an intrinsically unstructured protein that adopts a tertiary conformation only after binding to its different partners (Adkins and Lumb, 2002; Lacy et al., 2004).

The N-terminal domain I is necessary and sufficient for cyclin/CDK complex inhibition. This domain is subdivided in three regions: a cyclin binding domain, a CDK binding site and a 310 helix. The 310 helix is not required for binding to cyclin/CDKs but allows inhibition of Cyclin A/CDK2 and Cyclin E/CDK2 activity by inserting into the catalytic pocket of CDK2, thus blocking ATP hydrolysis, as reported for p27 (Russo et al., 1996; Hashimoto et al., 1998). This N-terminal domain also mediates the interaction with transcription factors such as b-Myb and MyoD (Reynaud et al., 2000; Joaquin and Watson, 2003). The PAPA domain is unique to p57 and may confer to p57 distinct functionalities from p21 and p27 via the interaction with different partners. For example, this central region of p57 interacts with the kinase LIMK1, a Rho effector involved in regulation of actin polymerization (Yokoo et al., 2003). Finally, the C-terminal QT domain of p57 shares homology with the C-termini of both p27 (QT motif) and p21 (PCNA binding site). Importantly, the PCNA binding site of p57 was found to participate in mediating growth inhibition (Watanabe et al., 1998) and gain-of-function mutations in this domain were later discovered to cause the development of growth-restriction syndromes such as IMAGE (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies) and Silver Russell (see below) (Arboleda et al., 2012; Brioude et al., 2013b). The QT domain of p57 also mediates interaction with the stress-activated protein kinase JNK1 (Chang et al., 2003). A putative Nuclear Localization Sequence (NLS) consensus site has been identified, at the C-terminus of p57 by homology with p27 (Lee et al., 1995). Finally, the C-terminus of p57 contains a consensus site for CDK2 phosphorylation on Thr310 in human (Thr329 in mice) that allows degradation of p57, similarly to Thr187 on p27 (Kamura et al., 2003).

The degradation of p57 is mediated by the proteasome. Phosphorylation of Thr310 by cyclin E/CDK2 complex creates a binding site for the F-box protein Skp2, leading to p57 ubiquitination by the Skp2-SCF (Skp1, Cullin, F-box) complex and to its degradation by the proteasome (Kamura et al., 2003). A second F-box protein, FBL12, has been involved in p57 degradation. In osteoblasts, TGFβ1 stimulates FBL12 expression that interacts with p57 phosphorylated on Thr310 and causes its proteasomal degradation independently of Skp2 (Kim et al., 2008).

ANIMAL MODELS OF p57
Knockout of Cdkn1c in mice (p57KO) causes embryonic (approximately 10% of mutant embryos die between E13 and E16) and perinatal lethality, with less than 10% of animals surviving to adulthood (Yan et al., 1997; Zhang et al., 1997). p57KO embryos display numerous developmental abnormalities that are mainly caused by defects in differentiation and increased apoptosis. For example, p57KO mice frequently
exhibit cleft palate, abdominal wall closure defects (umbilical hernia and omphalocele) associated with defective abdominal muscle development, truncation or shortening of the intestine, bone shortening and ossification delay due to defective chondrocyte differentiation, adrenal hyperplasia, renal dysplasia, and increased apoptosis in the lens (Table 1) (Yan et al., 1997; Zhang et al., 1997; Susaki et al., 2009). Consistent with Cdkn1c imprinting, animals inheriting a null allele from their mother (p57+/−/m) exhibit a phenotype similar to homozygous p57−/− animals. Importantly, a transgenic approach to insert a second Cdkn1c allele outside of the imprinted locus (i.e., two expressed copies of Cdkn1c) caused intrauterine growth restriction and embryonic lethality (Andrews et al., 2007). Thus, these studies have shown that unlike other CDK inhibitors, p57 is required for embryonic development and that expression of a single Cdkn1c allele is required.

Indeed, mice lacking p21 develop normally and are tumour free for the first 7 months (Deng et al., 1995), however aging mice (~16 months) spontaneously develop tumors of hematopoietic, endothelial or epithelial origin (Martin-Caballero et al., 2001). Consistent with its CDK inhibitory function, p21 loss accelerates the development of Ras-induced mammary and salivary tumors (Adnane et al., 2000). Similarly, p27 loss does not cause overt developmental defects, however p27KO mice are significantly larger and present multiple organ hyperplasia due to increased cell proliferation, and display retinal dysplasia and female sterility (Fero et al., 1996; Nakayama et al., 1996). p27 deficient animals spontaneously develop pituitary tumors within a few months and are dramatically more susceptible to carcinogenesis induced by genotoxic agents or oncogene activation (Fero et al., 1996, 1998; Nakayama et al., 1996). p27 deficient animals spontaneously develop pituitary tumors within a few months and are dramatically more susceptible to carcinogenesis induced by genotoxic agents or oncogene activation (Fero et al., 1996, 1998; Nakayama et al., 1996). Moreover, p27 acts as a haploinsufficient tumor suppressor, as p27 heterozygote mice also display a predisposition to tumor development induced by carcinogens or irradiation (Fero et al., 1998) or in conjunction with inactivation of another tumor suppressor such as PTEN (Di Cristofano et al., 2001). Finally, an inactivating mutation in p27 was discovered in rats as the cause of MENX (Multiple Endocrine Neoplasia X) syndrome. This mutation is a tandem duplication of eight nucleotides causing a frameshift leading to rapid degradation of p27 and decreased p27 protein level (Pellegata et al., 2006). Subsequently, six germline mutations of p27 have been identified as the origin of a rare MEN syndrome in humans called MEN4 (Pellegata et al., 2006; Marinoni and Pellegata, 2011).

A number of functional redundancies and compensatory mechanisms between CKIs have been highlighted by the generation of double or triple mutants, as well as knock-in mutants (Tables 1, 2). Interestingly, double p27−/−/p57KO or p21−/−/p57KO knockout in mice exacerbate certain phenotypes of p57KO mice. There is a worsening of placental and lens defects, and increased embryonic lethality in p27−/−/p57KO animals (Zhang et al., 1998). On the other hand, p21−/−/p57KO double mutation aggravates skeletal defects, and causes the appearance of phenotypes not observed in the single mutants, such as impaired lung and skeletal muscle development (Zhang et al., 1999). Triple p21−/−/p27−/−/p57KO knockout mice exhibit phenotypes similar to p27−/−/p57KO mice and die between E11.5 and E15.5 (Tateishi et al., 2012) (Table 2) (for detailed review see, Ciemerych and Sicinski, 2005).

In addition, a p57p27KO knock-in mouse model, where the coding sequence of p27 was inserted in the p57 locus, revealed significant functional redundancy between p27 and p57 when compared with p57KO mice, as p27 corrects certain phenotypes caused by the absence of p57, highlighting the importance of CDK inhibition by p57 during development (Table 1) (Susaki et al., 2009). Nevertheless, several phenotypes of p57KO mice, such as kidney dysplasia, abdominal wall defects or adrenal hyperplasia, are not restored in p57p27KO mutants, indicating that p57 plays specific functions during development (Table 1) (Susaki et al., 2009). Generation of another knock-in mutant, p57CK−, in which p57 no longer binds to cyclin/CDK complexes due to four point mutations, provided genetic evidence of

### TABLE 1 | Summary of phenotypes observed in p57KO, p57p27KO, and p57CK− mice.

| Genotypes | Phenotypes | References |
|------------|------------|------------|
| p57−/−     | Viable     | Deng et al., 1995 |
| p57p27−/−  | Viable     | Nakayama et al., 1996 |
| p21−/−     | Viable     | Fero et al., 1996 |
| p57p27−/−  | Lethal at birth | Yan et al., 1997 |
| p27−/−     | Lethal at birth | Zhang et al., 1997 |
| p21−/−     | Lethal at birth | Tateishi et al., 2012 |
| p21−/−     | Lethal at birth | Yamauchi et al., 2003 |
| p21−/−     | Lethal at birth | Zhang et al., 1999 |
| p21−/−     | Lethal at birth | Zhang et al., 1998 |
| p21−/−     | Embryonic lethal (E11.5,E15.5) | Tateishi et al., 2012 |
| p21−/−     | Embryonic lethal (E11.5,E15.5) | Tateishi et al., 2012 |
cyclin/CDK independent functions of p57 during development (Duquesnes et al., 2016). Indeed, some phenotypes of p57KO mice are completely absent in p57CK− mice, such as kidney dysplasia and intestinal shortening (Table 1). Surprisingly, others phenotypes, including adrenal hyperplasia and cleft palate, were aggravated or more frequent in p57CK− mice compared to p57KO, suggesting that in these tissues p57 plays both CDK dependent and independent roles (Table 1). A possible explanation for these phenotypes is that CDK-dependent degradation of the p57CK− protein is partly defective, leading to increased levels of the mutant protein, which could potentially exert a dominant negative effect (Duquesnes et al., 2016).

FUNCTIONS OF p57

Canonical Function in Cell Cycle Regulation

The role of Cip/Kip family proteins as CDK inhibitor is well-established, and like p21 and p27, p57 causes a cell cycle arrest in G1 (Sherr and Roberts, 1999; Besson et al., 2008). p57 is able to bind and inhibit all cyclin/CDK complexes, however, with a lower affinity for cyclin B/CDK1 and cyclin D2/CDK6 complexes (Matsuoka et al., 1995). p57 mediates cyclin/CDK complex inhibition by blocking the substrate interaction domain on cyclins and by insertion into the catalytic pocket of the CDKs, thus preventing binding of ATP and catalytic activity (Russo et al., 1996). Like other Cip/Kip proteins, p57 promotes the assembly of Cyclin D1-CDK4/6 complexes, which may remain active (Laber et al., 1997). Indeed, the CDK inhibitory activity of p27 and p21 is regulated by phosphorylation on Tyr88 and Tyr77, respectively, which relaxes the inhibitory conformation of the CKI, allowing partial CDK activation (Chu et al., 2007; Grimmler et al., 2007; James et al., 2008; Huang et al., 2015). This tyrosine is conserved in p57 (Tyr91), thus, a similar regulation of its CDK inhibitory activity by tyrosine kinases appears likely, although there is no direct evidence for this yet.

p57 can also inhibit the cell cycle via binding and inhibition of PCNA. Indeed, individual mutation of the CDK or PCNA binding site only results in partial loss of the growth inhibitory activity of p57 in vitro, whereas simultaneous loss of these two interactions completely abolishes the cell cycle inhibitory activity of p57 (Watanabe et al., 1998).

Finally, p57 also plays a role in trophoblast endoreplication. Endoreplication is a succession of G1 and S phases without intervening mitosis, leading to formation of giant polyplid cells. This phenomenon is observed during trophoblast differentiation to allow placenta implantation. p57 levels oscillate during endoreplication, decreasing before S phase entry and accumulating after S phase and in G1 (Hattori et al., 2000). p57KO mice exhibit placental defects and it was shown in vitro that p57 is required to trigger mouse trophoblast endoreplication by inhibiting CDK1 activity (Ullah et al., 2008; Susaki et al., 2009).

Non-canonical Functions of p57

In addition to cell cycle control, an increasing number of studies have described non-canonical functions of p57. The ability of p57 to regulate various cellular processes probably stems from its multi-domain structure and ability to interact with many protein partners. Indeed, a protein interactome has identified 183 direct potential partners of p57 involved in various cellular functions, including regulation of transcription, cytoskeleton and apoptosis (Duquesnes et al., 2016).

Cytoskeleton Regulation

All Cip/Kip family members have been shown to regulate cytoskeleton organization and cell migration by acting at different levels of the Rho/ROCK/LIMK/Cofilin pathway (Besson et al., 2004, 2008). In vivo, shRNA-mediated silencing of p57 delays neuronal migration in the cortex during development (Itoh et al., 2007) and p57 overexpression promotes radial migration of neural precursors (Tury et al., 2011). p57 is able to interact with LIMK1 via its unique central domain (Yokoo et al., 2003). LIMK1 is a serine/threonine kinase that promotes actin stress fiber assembly via phosphorylation of Cofilin, which inhibits its actin severing activity. LIMK1 is activated by the effectors of RhoA, ROCK1/2 (Rho-kinases) (Bernard, 2007). Binding of p57 to LIMK1 results in nuclear translocation and sequestration of LIMK1, which prevents Cofilin inhibition, resulting in decreased actin stress fiber formation (Yokoo et al., 2003). In agreement with these observations, p57 transfection into Schwann cells results in nuclear sequestration and inhibition of LIMK1, and a lack of Schwann cell differentiation (Heinen et al., 2008b). However, in HeLa cells the p57/LIMK1 interaction did not induce LIMK1 relocation in the nucleus, but increased its kinase activity, resulting in an increased number of stress fibers and decreased cell migration (Vlachos and Joseph, 2009). Similar findings were reported in hepatocellular carcinoma cells and decreased p57 levels in hepatocellular carcinoma samples correlated with the presence of metastases (Guo et al., 2015). In glioblastoma cells, p57 expression was also reported to inhibit cell migration and invasion (Sakai et al., 2004). Therefore, the role of p57 on cytoskeleton remodeling and migration appears to be mediated via its interaction with LIMK1 and to be dependent of the cellular context and subcellular location.

p57 and Apoptosis

Several phenotypes observed in p57KO mice can be attributed to an increase of apoptosis caused by hyperproliferation and/or differentiation defects. Interestingly, p57 has the ability to modulate apoptosis by different mechanisms, and both pro and anti-apoptotic roles have been reported depending on the cellular context, the signaling pathway involved and the stress to which cells are submitted (Rossi and Antonangeli, 2015).

p57 protects against apoptosis indirectly by inhibiting CDKs. In response to stress, p38 phosphorylates p57 on Thr143, which increases its affinity for CDK2 and results in G1 cell cycle arrest (Joaquin et al., 2012). p38 or p57 deficient MEFs (Mouse Embryonic Fibroblasts) exhibit decreased viability in response to osmotic or oxidative stress and UV exposure (Joaquin et al., 2012). Overexpression of p57 in HEK293 or HeLa cells can also protect against apoptosis indepdently of CDK inhibition by regulating the JNK/SAPK signaling pathway. In this model,
p57 interacts with JNK1 via its QT domain, preventing its interaction with c-Jun and thus inhibiting its kinase activity. Expression of the QT domain is sufficient to block JNK/SAPK-mediated apoptosis in response to UVs or MEKK overexpression (Chang et al., 2003).

Conversely, in a HeLa Tet-On derived cell line that overexpresses p57 after induction, p57 potentiates apoptosis in response to different stresses. p57 sensitized cells to apoptosis induced by genotoxic agents such as staurosorpine, cisplatin or etoposide, but had no effect on Fas-mediated apoptosis (Samuelsson et al., 2002; Vlachos et al., 2007). The pro-apoptotic effect of p57 in response to these drugs is CDK-independent and involves activation of the mitochondrial apoptosis pathway. In response to staurosorpine, p57 relocates to mitochondrial membranes and promotes Bax activation and a decrease of mitochondrial membrane potential, resulting in cytochrome-c release in the cytosol and activation of caspases 9 and 3 (Vlachos et al., 2007). The specificity of the mitochondrial pathway was confirmed by overexpression of Bcl-2, which prevented the pro-apoptotic effect of p57 (Vlachos et al., 2007). The mechanism by which p57 activates the mitochondrial pathway is dependent on its ability to interact and stimulate LIMK1 activity. LIMK1-induced stabilization of actin fibers causes the displacement of hexokinase I (HK-1), a regulatory enzyme of the VDAC (Voltage-dependent Anion Channel) mitochondrial channel, allowing mitochondrial membrane depolarization and thus activation of the mitochondrial apoptosis pathway. In response to staurosorpine, p57 relocates to mitochondrial membranes and promotes Bax activation and a decrease of mitochondrial membrane potential, resulting in cytochrome-c release in the cytosol and activation of caspases 9 and 3 (Vlachos et al., 2007). The specificity of the mitochondrial pathway was confirmed by overexpression of Bcl-2, which prevented the pro-apoptotic effect of p57 (Vlachos et al., 2007). The mechanism by which p57 activates the mitochondrial pathway is dependent on its ability to interact and stimulate LIMK1 activity. LIMK1-induced stabilization of actin fibers causes the displacement of hexokinase I (HK-1), a regulatory enzyme of the VDAC (Voltage-dependent Anion Channel) mitochondrial channel, allowing mitochondrial membrane depolarization and thus activation of the mitochondrial apoptosis pathway (Kavanagh et al., 2012). Finally, in H1299 non-small cell lung carcinoma cells, p57 transfection promoted p73β-mediated apoptosis in response to cisplatin, although the mechanism was not investigated (Gonzalez et al., 2005).

Regulation of Transcription by p57

Like other Cip/Kip family members, p57 can repress transcription indirectly via the inhibition of cyclin/CDK complexes, which prevents phosphorylation of Rb proteins and E2F transcription factors activation (Sher and Roberts, 1999; Besson et al., 2008). P57 also negatively regulates the activity of RNA polymerase II via its interaction with E2F1. The interaction with E2F1 allows the recruitment of p57 to DNA, where it inhibits CDK7 and CDK9, resulting in decreased phosphorylation of the C-terminal domain (CTD) of RNA polymerase II and leading to a decrease of global transcription (Ma et al., 2010). In addition to this CDK-dependent regulation, p57 may also directly regulate the activity of transcription factors.

Indeed, p57 binds directly to b-Myb and inhibits its transcriptional activity independently of CDKs (Joaquin and Watson, 2003). p57 is also involved in regulating the stability of the bHLH transcription factor MyoD. p57 promotes MyoD stability and muscle differentiation by inhibiting CDK2, preventing MyoD phosphorylation by CDK2 on Ser200, which destabilizes the protein (Reynaud et al., 1999). p57 also stabilizes MyoD in a CDK-independent manner by interacting directly with MyoD via its N-terminal 3H Helix region, protecting MyoD from degradation and promoting transcription of muscle genes (Reynaud et al., 2000). Similarly, p57 can interact directly with other bHLH transcription factors, including Ascl1 (Achaete-scute-like 1), NeuroD1 and Math2/NeuroD6 in neural progenitors. p57 then acts as a transcriptional repressor by directly inhibiting Ascl1 activity at target promoters, independently of CDKs (Joseph et al., 2009). Similarly, p57 can inhibit the transcriptional activity of Nurr1 independently of CDKs in vitro, and thus regulates dopaminergic neuron maturation (Joseph et al., 2003).

Finally, it was shown recently that p57 may also positively regulate transcription (Kullmann et al., 2020). P57 binds to and activates FHL2 (four-and-a-half LIM only protein 2), a multifunctional LIM domain only protein, which binds to and modulates the activity of several transcription factors, such as AP-1, β-catenin or the androgen receptor, by acting as a coactivator (Muller et al., 2000; Tran et al., 2016). FHL2 is inhibited by HDACs, and by binding to FHL2, p57 competes with HDAC1 and HDAC3 for FHL2 binding and prevents its inhibition (Kullmann et al., 2020).

Moreover, an interactome revealed that p57 has multiple partners involved in transcriptional regulation, including many transcription factors and HDAC7 (histone deacetylase 7), suggesting that p57 plays a major role in the regulation of transcription (Duquesnes et al., 2016).

p57 and Differentiation

p57 plays a key role in the differentiation of many cell types by inhibiting CDKs, promoting cell cycle exit, or via CDK-independent mechanisms. Several phenotypes observed in p57KO mice are caused by a delay or defect of differentiation (Yan et al., 1997; Zhang et al., 1997).

Several studies have shown that p57 regulates various aspects of neurogenesis, notably by controlling cell differentiation in the central and peripheral nervous system. p57 is present in neural stem cells and controls their fate by promoting differentiation into astrocytes at the expense of the oligodendrocyte lineage (Jadasz et al., 2012). In the peripheral nervous system, p57 inhibits Schwann cell differentiation and its silencing by shRNA results in cell cycle exit, cell growth and differentiation, as well as an increase of myelin production (Heinen et al., 2008a). Similarly, in the central nervous system, p57 inhibits oligodendrocyte differentiation (Kremer et al., 2009). However, other reports found that p57 promotes differentiation of oligodendrocyte progenitors in rat primary cells in vitro, as well as in vivo in zebrafish (Park et al., 2005; Dugas et al., 2007). In the nucleus, p57 interacts and inhibits Ascl1, a transcription factor promoting oligodendrocyte differentiation (Nakatani et al., 2013; Gottle et al., 2015). During oligodendrocyte differentiation, p57 relocates to the cytoplasm, promoting the export and inhibition of the transcriptional repressor Hes5 and relieving Ascl1 inhibition, enhancing differentiation (Gottle et al., 2015). In this study, p57 regulated the localization of LIMK1 and CDK2, which contributed to oligodendrocyte differentiation (Gottle et al., 2015). Thus, the effect of p57 on oligodendrocyte differentiation appears dependent on its subcellular localization. In addition to these cell types, p57 is involved in cell cycle exit of neural progenitors and in the specification of amacrine retinal
β appears to be a target of choice to promote the regeneration of syndrome lead to reduced infancy due to increased production of expression in human is associated with hyperinsulinism during of collagen X expression mediated by BMP2 (Stewart et al., 2004). p57 in the Regulation of Stem Cell Fate and p57 Functions

Several studies have revealed a crucial role of p57 in maintaining quiescence of resident adult stem cells in multiple tissues. p57 is required for hematopoietic stem cell quiescence and their maintenance. Indeed, in a conditional knockout model, p57 ablation in adult mice results in a decreased hematopoietic stem cell pool caused by an exit of quiescence state (G0) and induction of apoptosis (Matsumoto et al., 2011b). Reconstitution of the hematopoietic system after transplantation is also reduced in absence of p57 (Matsumoto et al., 2011b). These hematopoiesis defects are corrected by expression of p27 in the p57 locus (p57P27KI knock-in mice) (Matsumoto et al., 2011b). In hematopoietic stem cells of the fetal liver, p57 loss is accompanied by an increase of p27 expression, nevertheless neither p21 nor p27 knockout causes any defect, confirming that p57 is the primary CKI required for hematopoietic stem cell maintenance (Zou et al., 2011). Consistently, TGF-B1 induces quiescence of hematopoietic stem cells and increases p57 levels (Yamazaki et al., 2009). Conversely, increased Skp2 expression, which induces p57 degradation, is necessary for cell cycle reentry of hematopoietic stem cells (Rodriguez et al., 2011). The role of p57 in controlling hematopoietic stem cell quiescence involves its interaction with the chaperone Hsc70, which results in cytoplasmic sequestration of Hsc70/Cyclin D1 complexes, inhibiting cell cycle entry. Similarly, p27 may also interact with Hsc70 to compensate for the loss of p57 (Zou et al., 2011).

In the lung, homeostasis and tissue regeneration are supported by resident pulmonary stem cells called BASCs (Bronchioalveolar Stem Cells) (Kim et al., 2005; Liu et al., 2019; Salwig et al., 2019). The self-renewal of these stem cells requires a precise regulation of p57 expression levels. Indeed, either loss or increase of p57 expression in BASCs causes a lack of self-renewal, leading to defective tissue regeneration (Zacharek et al., 2011). These results highlight the importance of p57 imprinting and monoallelic expression. In the lung, Bmi1 controls the expression of p57 and other imprinted genes, however, no overt methylation changes at individual promoters or ICRs were observed in absence of Bmi1, suggesting that Bmi1 regulates imprinted gene expression by another mechanism (Zacharek et al., 2011). How p57 controls BASC maintenance has not yet been investigated.

In the adult hippocampus, p57 is expressed in quiescent neural stem cells and absent in proliferative progenitors. The presence of p57 is critical for maintaining neural stem cell quiescence and while p57 ablation initially leads to an increase in stem cell proliferation and stimulates neurogenesis, it results over time in the exhaustion of the neural stem cell population and impairs neurogenesis in aged mice (Furutachi et al., 2013). Similarly, NestinCre-driven deletion of p57 in the developing brain causes a decrease of Pax2+ interneuron progenitor number due to massive p53-dependent apoptosis, resulting in hydrocephalus (Matsumoto et al., 2011a). In contrast, during cortical development, p57KO embryos exhibit macrocephaly caused by an increased proliferation of neural progenitors and stem cells (Mairet-Coello et al., 2012). p57 appears to play a key role in timing cell cycle exit of specific neural progenitor populations, and p57 deregulation leads to abnormal development of specific neuron layers, especially during late neurogenesis (Mairet-Coello et al., 2012). A recent study using the MADM (mosaic analysis with double markers) system revealed that p57 regulates cortical neurogenesis by distinct mechanisms (Laukoter et al., 2020). p57 controls neural stem cell proliferation in a non-cell autonomous manner, with a complete knockout causing macrocephaly (Laukoter et al., 2020).
However, conditional deletion of p57 in radial precursor (Emx1+ cells) causes microcephaly due to p53-mediated apoptosis, in this case p57 exerts a cell-autonomous growth-promoting function by promoting survival of maturing cortical projection neurons (Laukoter et al., 2020), consistent with the NestinCre-driven phenotype previously observed (Matsumoto et al., 2011a). Interestingly, there is some contribution of the paternal allele during mouse brain development since NestinCre-driven deletion of the paternal allele results in reduced adult brain size due to increased apoptosis of neural progenitors and a slight reduction of proliferation (Imaizumi et al., 2020). These findings are consistent with earlier observations that p57 exhibits biallelic expression in the developing brain (Matsuoka et al., 1996). Finally, p57 was recently involved in neural stem cell fate determination. In Drosophila, neural stem cells can enter a quiescence state either in G0 or G2 (25 and 75%, respectively) that determines their fate, as G2 blocked cells can be rapidly activated to divide in response to nutritional stimuli, while G0 cells respond more slowly (Otsuki and Brand, 2018). The choice between these two types of quiescence is determined at the embryonic stage and depends on the presence of the p57 homolog. Dacapo, which favors entry in the G0 quiescent state at the expense of the G2 one (Otsuki and Brand, 2019). Dacapo deletion leads to a change in the fate of the neural stem cells, which are then preferentially oriented toward a G2 quiescence state (Otsuki and Brand, 2019).

In the developing skeletal muscle, p57 inhibition is required for maintenance of certain stem/progenitor cells. Notch inhibits p57 expression in Pax3+/+ muscle progenitors via Hes1, allowing amplification of the progenitor pool (Zalc et al., 2014). Loss of Notch signaling leads to an increase of p57 expression in muscle progenitors, which is associated with precocious differentiation and progenitor depletion (Zalc et al., 2014). In adult muscle, satellite cells, the resident stem cells, derive from Pax3+/+ progenitors and are mobilized in case of damage to regenerate muscle fibers. Surprisingly, p57 is not expressed in quiescent satellite cells but is induced during their mobilization (Mademtzoglou et al., 2018). In addition, loss of p57 in vivo increases proliferation and self-renewal of progenitors and myoblasts at the expense of their differentiation, and in case of damage, p57 absence causes satellite cell depletion and delays muscle regeneration (Mademtzoglou et al., 2018).

Finally, the presence of p57 was reported in other quiescent adult tissue stem cells, such as hair follicle stem cells (Leishman et al., 2013) as well as in Mex3aHigh quiescent intestinal stem cells (Barriga et al., 2017), suggesting that p57 plays a general role in the maintenance of resident stem cells.

### p57 IN HUMAN PATHOLOGIES

Deregulation of imprinting of the 11p15.5 locus, as well as loss of heterozygosity (LOH) or point mutations of CDKN1C are responsible for the development of several hereditary pathologies and may contribute to cancer development and progression. Alterations that cause loss of p57 function lead to the development of the Beckwith–Wiedemann syndrome, while p57 gain of function leads to the development of Silver-Russell and IMAGe syndromes.

#### Beckwith–Wiedemann Syndrome

Beckwith–Wiedemann syndrome (BWS) (OMIM # 130650) is a rare genetic disorder with a prevalence of 1/13700 births, characterized by excessive growth, developmental anomalies and tumor predisposition during childhood. BWS has a highly variable presentation and patients usually display only a subset of phenotypes. Diagnosis is based on the presence of at least three major criteria (macrosomia, macroglossia, abdominal wall defects, hemihyperplasia, embryonal tumors, renal abnormalities, anterior ear lobe creases) or the association of two major criteria with at least one minor phenotype (neonatal hypoglycemia, characteristic facies, diastasis recti, cardiomegaly/structural cardiac anomalies...) (Weksberg et al., 2010). A molecular anomaly, of epigenetic or genetic origin, in the 11p15.5 region is identified in approximately 80% of BWS patients. Most epigenetic abnormalities are mosaic, meaning that only a fraction of the cells carry the molecular defect. The severity and penetrance of the phenotypes therefore depends on the underlying molecular mechanism and the percentage of mosaicism (Brioude et al., 2013a).

The majority of BWS patients present epigenetic abnormalities. Loss of ICR2 methylation on the maternal allele is the most common form and is observed in 50% of patients (Eggermann et al., 2014b). This anomaly results in biallelic expression of KCNQ1OT1 and thus in loss of CDKN1C expression (Figure 1) (Eggermann et al., 2014b). Patients with anomalies of this centromeric region have a more severe phenotype and exhibit macroglossia and abdominal wall defects. Gain of methylation on ICR1 is observed in 5% of cases, resulting in biallelic expression of IGF2. Patients with this defect display a higher risk of developing tumors and organomegaly (Weksberg et al., 2010; Brioude et al., 2013a). Several genetic alterations are also responsible for BWS development. Among genetic anomalies, paternal isodisomies (UPD = Uniparental Disomy) are found in approximately 20% of patients. UPDs correspond to the duplication of the paternal 11p15.5 locus, with no maternal contribution for this region, thus leading to biallelic IGF2 expression and loss of CDKN1C expression (Weksberg et al., 2010). Patients with UPDs have an increased risk of hemihyperplasia (Brioude et al., 2013a). Other chromosomal rearrangements have also been reported in rare (2–3%) cases, including extensive paternal duplications, carrying both ICR1 and ICR2 regions (1%), translocations/inversion (1%), which are usually transmitted by the mother, as well as ICR microdeletions (<1%) (Weksberg et al., 2010; Eggermann et al., 2014a). Finally, maternally inherited point mutations in CDKN1C are observed in 5% of sporadic cases and are responsible for the majority of familial cases (50%) of BWS (Eggermann et al., 2014b). Patients with CDKN1C mutations have particular phenotypes: almost all of them display abdominal wall defects (umbilical hernia or omphalocele) and have an increased incidence of cleft palate, genital anomalies and polydactyly (Romanelli et al., 2010). Mutations of CDKN1C described in BWS cover the entire coding region. They are mostly nonsense
mutations leading to truncation of the protein or mutations causing a frameshift, which strongly alters the structure of the protein. Some missense mutations have also been described in the cyclin/CDK binding domain (Eggermann et al., 2014b; Brioude et al., 2015).

Silver Russell and IMAGe Syndromes
In opposition to BWS, p57 gain of function mutations are associated with two very rare disorders, Silver-Russell syndrome (SRS) (OMIM # 180860) (1/100,000 birth) (Brioude et al., 2013b) and IMAGe syndrome (Intrauterine Growth Retardation, Metaphyseal dysplasia, Adrenal insufficiency, Genital abnormalities) (OMIM # 614732) (only a few dozen cases reported worldwide) (Arboleda et al., 2012). These pathologies cause opposite phenotypes to BWS and share a number of features, notably intrauterine growth retardation (Eggermann et al., 2014b).

The study of a familial form of IMAGe syndrome led to the identification of five missense mutations located in the PCNA binding domain of p57 (Arboleda et al., 2012). Expression of a transgene carrying these mutations in Drosophila caused decreased eye, wing and vascular network size, consistent with a gain of function in p57 (Arboleda et al., 2012). In vitro, these mutations were found to decrease binding to PCNA and to impair p57 ubiquitination, leading to p57 stabilization and inhibition of proliferation (Arboleda et al., 2012; Borges et al., 2015). Interestingly, mutation in DNA polymerase ε were recently identified in 15 cases of IMAGe syndrome (Logan et al., 2018). Given the impact of p57 mutations found in IMAGe on its interaction with PCNA, it would be interesting to investigate further their effect on PCNA function, DNA replication and S phase progression.

The most frequent molecular anomalies in SRS patients are loss of ICR1 methylation (60% of cases), which result in biallelic expression of H19 and thus loss of IGF2 expression. Chromosomal rearrangements with maternal duplications of the centromeric domain, containing ICR2, or of both domains have also been observed (Wakeling et al., 2017). Nevertheless, point mutations in CDKN1C causing a gain of function in p57 were recently found to cause SRS. Indeed, a gain of function mutation in the PCNA binding domain of p57 was identified in a familial form of SRS (Brioude et al., 2013b). Interestingly, the residue mutated (Arg279Leu) is also mutated in IMAGe syndrome (Arg279Pro). Tissue culture experiments suggest that this mutation in p57 does not affect the cell cycle but leads to stabilization of the protein, consistent with the ubiquitination defect previously observed in IMAGe syndrome (Brioude et al., 2013b).

p57 and Cancer
Like other CKIs, p57 is a putative tumor suppressor. However, the lethality of p57KO mice has so far prevented to test this formally in vivo and the involvement of p57 in cancers remains to be addressed in animal models. Nevertheless, several lines of evidence indicate that p57 plays a role in carcinogenesis. For instance, BWS patients are predisposed to tumor development (Weksberg et al., 2010) and decreased p57 expression is observed in many types of tumors, including in gastric, colorectal, pancreatic, pulmonary, and mammary carcinomas, as well as in leukemia (Li et al., 2003; Pateras et al., 2009; Borriello et al., 2011; Kavanagh and Joseph, 2011; Weis et al., 2015). Moreover, decreased p57 expression correlates with aggressiveness in several types of tumors and is associated with poor prognosis (Kavanagh and Joseph, 2011; Qiu et al., 2018). Interestingly, CDKNJC mutations are not frequently observed in cancers (Pateras et al., 2009). Loss of p57 expression in human carcinomas is caused predominantly by loss of heterozygosity of the 11p15.5 locus, methylation of the CDKNJC promoter, and histone methylations (Kikuchi et al., 2002; Pateras et al., 2006; Weis et al., 2015). In fact, loss of imprinting of KCNQ1OT1 has been observed in colorectal cancer samples, but did not necessarily correlated with p57 expression (Nakano et al., 2006). However, loss of p57 expression has been observed in colorectal cancer, mainly due to promoter hypermethylation (Kikuchi et al., 2002) and it was shown that the expression of the methyltransferase DNMT3a is strongly increased in colorectal tumors (Weis et al., 2015). Consistently, DNMTa deletion inhibits tumor formation in vivo at least in part by increasing p57 expression (Weis et al., 2015). Moreover, several miRNAs and LncRNAs have also been shown to repress p57 in various cancers, as described earlier (Kavanagh and Joseph, 2011; Stampone et al., 2018). Finally, loss of p57 may also be due to increased degradation caused by Skp2 overexpression (Pateras et al., 2006).

CONCLUSION
p57Kip2 has the particularity of being the only CDK inhibitor required for embryonic development. Since its discovery as a cyclin/CDK inhibitor, a growing number of studies have shown that p57 is a multifunctional protein involved in the regulation of other cellular processes such as cell migration, differentiation, apoptosis, transcriptional regulation or stem cell specification and fate. The generation of a p57CK− knock-in mouse model has provided genetic evidence that some of its functions are independent of cyclins/CDKs during development, yet the underlying mechanisms remain largely unknown. How p57 is regulated also remains largely unclear. In view of its multiple functions, a better understanding of p57’s functions and regulation would improve our comprehension of normal development and of the etiology of several genetic disorders and cancers. The fact that p57 is subjected to paternal imprinting makes it particularly vulnerable to genetic alterations leading to loss (BWS, cancer) or gain (IMAGe and SRS) of function of the only active allele. In addition to complex developmental growth disorders, p57 down-regulation is associated with the development of cancers and its decreased expression is correlated with aggressiveness in several tumor types. For example, decreased p57 expression correlates with poor clinical outcome in breast cancer (Yang et al., 2009). Similarly, p57 levels are inversely related to tumor growth and cancer stage in non-small cell lung cancer, hepatocellular and pancreatic carcinomas and others (Ito et al., 2001a,b; Pateras et al., 2006). Interestingly, in colorectal cancer, p57 levels are increased in low grade adenomas and
finally decrease in primary carcinomas (Li et al., 2003), perhaps reflecting a mechanism to initially limit tumor progression. Similarly, in Wilm’s tumor, loss of heterozygosity of the 11p15.5 locus is associated with the reactivation of the paternal allele of p57, possibly to limit cell proliferation and cancer progression (Overall et al., 1996; Taniguchi et al., 1997). To conclude, several lines of evidence indicate a prominent role for p57 during tumorigenesis and stem cell regulation, and a significant number of studies suggest that p57 is a pertinent prognostic marker and that it may hold therapeutic potential both for anticancer treatment and to manipulate tissue progenitor/stem cells for regenerative medicine.

REFERENCES

Adkins, J. N., and Lumb, K. J. (2002). Intrinsic structural disorder and sequence features of the cell cycle inhibitor p57Kip2. Proteins 46, 1–7. doi: 10.1002/prot.10018
Adrane, J., Jackson, R. J., Niccoia, S. V., Cantor, A. B., Pledger, W. J., and Sebti, S. M. (2000). Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene 19, 5338–5347. doi: 10.1038/sj.onc.1203956
Andrews, S. C., Wood, M. D., Tunster, S. J., Barton, S. C., Surani, M. A., and John, R. M. (2007). Cdkn1c (p57Kip2) is the major regulator of embryonic growth within its imprinted domain on mouse distal chromosome 7. BMC Dev. Biol. 7:53. doi: 10.1186/1471-213X-7-53
Arboleda, V. A., Lee, H., Parnaik, R., Fleming, A., Banerjee, A., Ferraz-De-Souza, B., et al. (2012). Mutations in the PCNA-binding domain of Cdkn1C cause image syndrome. Nat. Genet. 44, 788–792. doi: 10.1038/ng.2275
Asahara, S., Etoh, H., Inoue, H., Teruyama, K., Shibutani, Y., Ihara, Y., et al. (2015). Paternal allelic mutation at the Cncn1 locus reduces pancreatic beta-cell mass by epigenetic modification of Cdkn1c. Proc. Natl. Acad. Sci. U.S.A. 112, 8332–8337. doi: 10.1073/pnas.1422104112
Avrahami, D., Li, C., Yu, M., Jiao, Y., Zhang, J., Naji, A., et al. (2014). Targeting the binding site of CDKN1C inhibit cell proliferation by impairing the entry into S phase. Mol. Cancer Res. 12, 281–294. doi: 10.1158/1541-7786.MCR-13-0537
Besson, A., Dowdy, S. F., and Roberts, J. M. (2008). CDK inhibitors: cell cycle regulators and beyond. Dev. Cell 14, 159–219. doi: 10.1016/j.devcel.2008.01.013
Borges, K. S., Arboleda, V. A., and Vilain, E. (2015). Mutations in the PCNA-binding site of Cdkn1C inhibit cell proliferation by impairing the entry into S phase. Cell Div. 10:2. doi: 10.1186/s13008-015-0008-8
Borrelli, A., Caldarelli, L., Bencivenga, D., Criscuolo, M., Cucciolia, V., Tramontano, A., et al. (2011). p57(Kip2) and cancer: time for a critical appraisal. Mol. Cancer Res. 9, 1269–1284. doi: 10.1158/1541-7786.MCR-11-0220
Brioude, F., Lacoste, A., Netchine, I., Vazquez, M. P., Auber, F., Audry, G., et al. (2013a). Beckwith-Wiedemann syndrome: growth pattern and tumor risk according to molecular mechanisms, and guidelines for tumor surveillance. Horm. Res. Paediatr. 80, 457–465. doi: 10.1159/000355544
Brioude, F., Oliver-Petit, I., Blaise, A., Praz, F., Rossignol, S., Le Jule, M., et al. (2013b). Cdkn1C mutation affecting the Pca-binding domain as a cause of familial Russell Silver syndrome. J. Med. Genet. 50, 823–830. doi: 10.1136/jmedgenet-2013-101691
Brioude, F., Netchine, I., Praz, F., Le Jule, M., Calmel, C., Lacombe, D., et al. (2015). Mutations of the imprinted Cdkn1c gene as a cause of the overgrowth Beckwith-Wiedemann syndrome: clinical spectrum and functional characterization. Hum. Mutat. 36, 894–902. doi: 10.1002/humu.22284
Busanello, A., Battistelli, C., Carbone, M., Mostocotto, C., and Maione, R. (2012). MyoD regulates p57kip2 expression by interacting with a distinct cis-element and modifying a higher order chromatin structure. Nucleic Acids Res. 40, 8266–8275. doi: 10.1093/nar/gks619
Chang, T. S., Kim, M. J., Ryoo, K., Park, J., Eom, S. J., Shim, J., et al. (2003). p57KIP2 modulates stress-activated signaling by inhibiting c-Jun.Nh2-terminal kinase/stress-activated protein Kinase. J. Biol. Chem. 278, 48092–48098. doi: 10.1074/jbc.m309421200
Chen, X. Y., Zhang, J., and Zhu, J. S. (2019). The role of mi6A RNA methylation in human cancer. Mol. Cancer 18:103. doi: 10.1186/s12943-019-1033-z
Chu, I., Sun, J., Arnaout, A., Kahn, H., Hanna, W., Narod, S., et al. (2007). p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 128, 281–294. doi: 10.1016/j.cell.2006.11.049
Cierny, M. A., and Sicsinski, P. (2005). Cell cycle in mouse development. Oncogene 24, 2877–2898. doi: 10.1038/sj.onc.1206668
Cioffi, M., Trabulo, S. M., Sanchez-Ripoll, Y., Miranda-Lorenzo, I., Lonardo, E., Durado, J., et al. (2015). The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut 64, 1936–1948. doi: 10.1136/gutjnl-2014-308470
Deng, C., Zhang, P., Harper, J. W., Elledge, S. J., and Leder, P. (1995). Mice lacking p21cip1/waf1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 673–684. doi: 10.1016/0092-8674(95)90039-x
Di Cristofano, A., De Acetis, M., Koff, A., Cardono-Cardo, S., and Pandolfi, P. P. (2001). Pten and p27kip1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27, 222–224. doi: 10.1038/84879
Dugas, J. C., Ibrahim, A., and Barres, B. A. (2007). A crucial role for p57(Kip2) in the intracellular timer that controls oligodendrocyte differentiation. J. Neurosci. 27, 6185–6196. doi: 10.1523/jneurosci.0628-07.2007
Duquesnes, N., Callot, C., Jeannot, P., Gaburon, V., Nakayama, K. I., Manenti, S., et al. (2016). p57(Kip2) knock-in mouse reveals CDK-independent contribution in the development of Beckwith-Wiedemann syndrome. J. Pathol. 239, 250–261. doi: 10.1002/path.4721
Dyer, M. A., and Cepko, C. L. (2000). p57(Kip2) regulates progenitor cell proliferation and amacrine interneuron development in the mouse retina. Development 127, 3593–3606
Eggermann, T., Algar, E., Lapunzina, P., Mackay, D., Her, E. R., Mannens, M., et al. (2014a). Clinical utility gene card for: Beckwith-Wiedemann Syndrome. Eur. J. Hum. Genet. 22. doi: 10.1038/ejhg.2013.132
Eggermann, T., Binder, G., Brioude, F., Maione, R. E., Lapunzina, P., Cabellis, M. V., et al. (2014b). Cdkn1C mutations: two sides of the same coin. Trends Mol. Med. 20, 614–622. doi: 10.1016/j.molmed.2014.09.001
Fatica, A., and Bozzoni, I. (2014). Long non-coding RNAs: new players in cell differentiation and development. Nat. Rev. Genet. 15, 7–21. doi: 10.1038/nrg3606
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., and Kemp, C. J. (1998). The p57kip2 shutoff domain is not required for MyoD regulation in vivo. J. Biol. Chem. 273, 28155–28165. doi: 10.1074/jbc.273.42.28155
Fero, M. L., Rivkin, M., Tash, M., Porter, P., Carow, C. E., Firpo, E., et al. (1996). A syndrome of multigorgan hyperplaasia with features of gigantism, tumorigenesis,
Hirata, M., Kugimiya, F., Fukai, A., Ohba, S., Kawamura, N., Ogasawara, T., Fitzpatrick, G. V., Soloway, P. D., and Higgins, M. J. (2002). Regional loss of p57Kip2 protein family are regulated by non-receptor tyrosine kinases. *J. Mol. Biol. 427, 371–386.* doi: 10.1016/j.jmb.2014.11.011

Imaiizumi, Y., Furutachi, S., Watanabe, T., Miya, H., Kawaguchi, D., and Gotoh, Y. (2020). Role of the imprinted allele of the Cdkn1c gene in mouse neocortical development. *Sci. Rep. 10:* 1884. doi: 10.1038/s41598-020-58629-9

Ito, Y., Takeda, T., Sakon, M., Tsujimoto, M., Mondon, M., and Matsuura, N. (2001a). Expression of p57/Kip2 protein in hepatocellular carcinoma. *Oncology 61,* 221–225. doi: 10.1159/000055378

Ito, Y., Takeda, T., Wakasa, K., Tsujimoto, M., and Matsuura, N. (2001b). Expression of p57Kip2 protein in pancreatic adenocarcinoma. *Pancreas 23,* 246–250. doi: 10.1067/mpe.200110000-00004

Itoh, Y., Masuyama, N., Nakayama, K., Nakayama, K., and Gotoh, Y. (2007). The cyclin-dependent kinase inhibitors p57 and p27 regulate neuronal migration in the developing mouse neocortex. *J. Biol. Chem. 282,* 399–396. doi: 10.1074/jbc.m80944920

Jadasz, J. J., Rivera, F. J., Taubert, A., Kandasamy, M., Sandner, B., Weidner, N., et al. (2012). p57Kip2 regulates gial fate decision in adult neural stem cells. *Development 139,* 3306–3315. doi: 10.1242/dev.074518

James, M. K., Ray, A., Lezszina, D., and Blain, S. W. (2008). Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity. *Mol. Cell Biol. 28,* 498–510. doi: 10.1128/mcb.02171-06

Jia, J., Lin, M., Zhang, L., York, J. P., and Zhang, P. (2007). The Notch signaling pathway controls the size of the olfactory lens by directly suppressing p57Kip2 expression. *Mol. Cell Biol. 27,* 7236–7247. doi: 10.1128/mcb.00780-07

Jirawatnotai, S., Moons, D. S., Stocco, C. O., Franks, R., Hales, D. B., Gibori, G., et al. (2003). The cyclin-dependent kinase inhibitors p27Kip1 and p21Waf1 cooperate to restrict proliferative life span in differentiating ovarian cells. *J. Biol. Chem. 278,* 17021–17027. doi: 10.1074/jbc.M301206200

Joaquín, M., Guerín, A., Gonzalez-Nunez, D., Josue Ruiz, E., Ferreiro, I., De Nadal, E., et al. (2012). The p57 Cdk1 integrates stress signals into cell-cycle progression to promote cell survival under stress. *J. Cell Biol. 31,* 2952–2964. doi: 10.1083/emo.2012.122

Joaquín, M., and Watson, R. J. (2003). The cell cycle-regulated B-myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57Kip2 by interacting with its cyclin-binding domain. *J. Biol. Chem. 278,* 44225–44226. doi: 10.1074/jbc.M308933200

Joseph, B., Andersson, E. R., Vlachos, P., Sodersten, E., Liu, L., Teixeira, A. L., et al. (2009). p57Kip2 is a repressor of Mash1 activity and neuronal differentiation in neural stem cells. *Cell Death Differ. 16,* 1256–1265. doi: 10.1038/cdd.2009.72

Joseph, B., Wallen-Mackenzie, A., Benoit, G., Murata, T., Joodmaid, E., Okret, S., et al. (2003). p57Kip2 cooperates with Nurr1 in developing dopamine cells. *Proc. Natl. Acad. Sci. U.S.A. 100,* 15619–15624. doi: 10.1073/pnas.1831009100

Kassem, S. A., Ariel, I., Thornton, P. S., Hussain, K., Smith, V., Lindley, K. J., et al. (2010). Regulation of p57Kip2 by Egr1, Sp1 and DNA demethylation. *Oncology 75,* 805–816. doi: 10.1159/000055378

Kawamura, T., Hara, T., Kotoshiba, S., Yada, M., Ishida, N., Imaki, H., et al. (2003). Expression of p57/Kip2 protein in hepatocellular carcinoma. *Oncology 61,* 221–225. doi: 10.1159/000055378

Kerns, S. L., Guevara-Aguirre, J., Andrew, S., Geng, J., Guevara, C., Guevara-Cervantes, J. et al. (2012). Oligodendroglial maturation is dependent on intracellular protein shuttling. *J. Neurosci. 32,* 970–981. doi: 10.1523/jneurosci.11059-12.2012

Kim, M., Nakamoto, T., Nishimori, S., Tanaka, K., and Chiba, T. (2008). A novel ubiquitin ligase involved in p57Kip2 proteolysis regulates osteoblast cell differentiation. *Eemb Rep. 9,* 878–884. doi: 10.1038/embob.2008.125
Creff and Besson

Kim, Y. K., Yu, J., Han, T. S., Park, S. Y., Namkoong, B., Kim, D. H., et al. (2009). Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. *Nucleic Acids Res.* 37, 1672–1681. doi: 10.1093/nar/gkp002

Kremer, D., Heinzen, I. J., Jadass, J., Gottle, P., Zimmermann, K., Zickler, P., et al. (2009). pSki2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation. *Proc. Natl. Acad. Sci. U.S.A.* 106, 9087–9092. doi: 10.1073/pnas.0902004106

Kullmann, M. K., Podmirseg, S. R., Roilo, M., and Hengst, L. (2020). The Cdk inhibitor p57 (Kip2) enhances the activity of the transcriptional coactivator FHL2. *Sci. Rep.* 10:7140. doi: 10.1038/s41598-020-62641-4

Laber, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., et al. (1997). New functional activities for the p21 family of CDK inhibitors. *Genes Dev.* 11, 847–862. doi: 10.1101/gad.11.7.847

Lacy, E. R., Filipovic, I., Lewis, W. S., Ottieno, S., Xiao, L., Weiss, S., et al. (2004). p27 binds cyclin-CDK complexes through a sequential mechanism involving binding-induced protein folding. *Nat. Struct. Mol. Biol.* 11, 358–364. doi: 10.1038/nsmb746

Laukoter, S., Beattie, R., Pauler, F. M., Amberg, N., Nakayama, K. I., and Hinnenpeyn, S. M. (2020). Imprinted Cdkn1c genomic locus cell-autonomously promotes cell survival in cerebral cortex development. *Nat. Commun.* 11:195. doi: 10.1038/s41467-019-14077-2

Lee, M. H., Reynisdottir, I., and Massague, J. (1995). Cloning of p57kIP2, a novel cyclin-dependent kinase inhibitor. *Cell* 81, 2197–2208. doi: 10.1016/0092-8674(95)80031-7

Leighton, P. A., Saam, J. R., Ingram, R. S., Stewart, C. L., and Tilghman, S. M. (1993). Drosophila and human 11p15.5 have the same parent of origin for imprinted genes. *Proc. Natl. Acad. Sci. U.S.A.* 90, 8576–8580. doi: 10.1073/pnas.90.19.8576

Mairet-Coello, G., Tury, A., Van Buskirk, E., Robinson, K., Genestine, M., and Dicicco-Bloom, E. (2012). p57(Kip2) regulates radial glia and intermediate progenitor cell dynamics and lower layer neurogenesis in developing cerebral cortex. *Development* 139, 475–487. doi: 10.1242/dev.073714

Malumbres, M., and Barbacid, M. (2005). Mammalian cyclin-dependent kinases. *Trends Biochem. Sci.* 30, 630–641. doi: 10.1016/j.tibs.2005.09.005
Pandey, R. R., Mondal, T., Mohammad, F., Enroth, S., Redrup, L., Komorowski, J., et al. (2008). Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Mol. Cell 32, 232–246. doi: 10.1016/j.molcel.2008.08.022

Park, H. C., Boyce, J., Shin, J., and Appel, B. (2003). Oligodendrocyte specification in zebrafish requires Notch-regulated cyclin-dependent kinase inhibitor function. J. Neurosci. 25, 6838–6844. doi: 10.1523/jneurosci.0981-05.2005

Pateras, I. S., Apostolopoulou, K., Koutsami, M., Evangelou, K., Tsantoulis, P., Lioligolou, T., et al. (2006). Downregulation of the Kip family members p27(Kip1) and p57(Kip2) by SKP2 and the role of methylation in p57(Kip2) inactivation in nonsmall cell lung cancer. Int. J. Cancer 119, 2546–2556. doi: 10.1002/ijc.22214

Pateras, I. S., Apostolopoulou, K., Niforou, K., Kotsinas, A., and Gorgoulis, V. G. (2009). p57Kip2: “Kip”ing the cell under control. Int. J. Cancer 125, 2546–2556. doi: 10.1002/ijc.24312

Pateras, I. S., Apostolopoulou, K., Niforou, K., Kotsinas, A., Gorgoulis, V. G., and Scandura, J. M. (2011). The SKP2 E3 ligase regulates basal homeostasis and stress-induced cell survival in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 108, 15558–15563. doi: 10.1073/pnas.0806387108

Pateras, I. S., Apostolopoulou, K., Niforou, K., Kotsinas, A., Gorgoulis, V. G., and Scandura, J. M. (2011). The SKP2 E3 ligase regulates basal homeostasis and stress-induced cell survival in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 108, 15558–15563. doi: 10.1073/pnas.0806387108

Pateras, I. S., Apostolopoulou, K., Niforou, K., Kotsinas, A., and Gorgoulis, V. G. (2009). p57Kip2: “Kip”ing the cell under control. Int. J. Cancer 125, 2546–2556. doi: 10.1002/ijc.24312

Pateras, I. S., Apostolopoulou, K., Niforou, K., Kotsinas, A., Gorgoulis, V. G., and Scandura, J. M. (2011). The SKP2 E3 ligase regulates basal homeostasis and stress-induced cell survival in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 108, 15558–15563. doi: 10.1073/pnas.0806387108

Pateras, I. S., Apostolopoulou, K., Niforou, K., Kotsinas, A., Gorgoulis, V. G., and Scandura, J. M. (2011). The SKP2 E3 ligase regulates basal homeostasis and stress-induced cell survival in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 108, 15558–15563. doi: 10.1073/pnas.0806387108

Pateras, I. S., Apostolopoulou, K., Niforou, K., Kotsinas, A., Gorgoulis, V. G., and Scandura, J. M. (2011). The SKP2 E3 ligase regulates basal homeostasis and stress-induced cell survival in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 108, 15558–15563. doi: 10.1073/pnas.0806387108

Pateras, I. S., Apostolopoulou, K., Niforou, K., Kotsinas, A., Gorgoulis, V. G., and Scandura, J. M. (2011). The SKP2 E3 ligase regulates basal homeostasis and stress-induced cell survival in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 108, 15558–15563. doi: 10.1073/pnas.0806387108

Pedrazzoli, S., Scopelliti, M., Berti, E., Sonzogni, A. L., and Fazi, A. (2012). p57Kip2 regulates cyclin-D1 expression and associates with EZH2 in breast cancer. Stem Cells 30, 243–253. doi: 10.1002/stem.842

Peinado, H., Paricio, C., and Zabalgoitia, J. M. (2007). p57Kip2 is required for the directional migration of neural progenitors. Nature 448, 121–125. doi: 10.1038/nature05941

Peng, Y., Zhang, Y., and Zhou, J. (2010). p57Kip2 inhibits Tor treatment-induced cell proliferation, autophagy and cell death in prostate cancer cells. Exp. Cell Res. 316, 91–101. doi: 10.1016/j.yexcr.2009.11.011

Peng, Y., Zhang, Y., and Zhou, J. (2010). p57Kip2 inhibits Tor treatment-induced cell proliferation, autophagy and cell death in prostate cancer cells. Exp. Cell Res. 316, 91–101. doi: 10.1016/j.yexcr.2009.11.011

Peng, Y., Zhang, Y., and Zhou, J. (2010). p57Kip2 inhibits Tor treatment-induced cell proliferation, autophagy and cell death in prostate cancer cells. Exp. Cell Res. 316, 91–101. doi: 10.1016/j.yexcr.2009.11.011

Peng, Y., Zhang, Y., and Zhou, J. (2010). p57Kip2 inhibits Tor treatment-induced cell proliferation, autophagy and cell death in prostate cancer cells. Exp. Cell Res. 316, 91–101. doi: 10.1016/j.yexcr.2009.11.011

Peng, Y., Zhang, Y., and Zhou, J. (2010). p57Kip2 inhibits Tor treatment-induced cell proliferation, autophagy and cell death in prostate cancer cells. Exp. Cell Res. 316, 91–101. doi: 10.1016/j.yexcr.2009.11.011

Peng, Y., Zhang, Y., and Zhou, J. (2010). p57Kip2 inhibits Tor treatment-induced cell proliferation, autophagy and cell death in prostate cancer cells. Exp. Cell Res. 316, 91–101. doi: 10.1016/j.yexcr.2009.11.011

Peng, Y., Zhang, Y., and Zhou, J. (2010). p57Kip2 inhibits Tor treatment-induced cell proliferation, autophagy and cell death in prostate cancer cells. Exp. Cell Res. 316, 91–101. doi: 10.1016/j.yexcr.2009.11.011

Peng, Y., Zhang, Y., and Zhou, J. (2010). p57Kip2 inhibits Tor treatment-induced cell proliferation, autophagy and cell death in prostate cancer cells. Exp. Cell Res. 316, 91–101. doi: 10.1016/j.yexcr.2009.11.011

Peng, Y., Zhang, Y., and Zhou, J. (2010). p57Kip2 inhibits Tor treatment-induced cell proliferation, autophagy and cell death in prostate cancer cells. Exp. Cell Res. 316, 91–101. doi: 10.1016/j.yexcr.2009.11.011

Peng, Y., Zhang, Y., and Zhou, J. (2010). p57Kip2 inhibits Tor treatment-induced cell proliferation, autophagy and cell death in prostate cancer cells. Exp. Cell Res. 316, 91–101. doi: 10.1016/j.yexcr.2009.11.011

Peng, Y., Zhang, Y., and Zhou, J. (2010). p57Kip2 inhibits Tor treatment-induced cell proliferation, autophagy and cell death in prostate cancer cells. Exp. Cell Res. 316, 91–101. doi: 10.1016/j.yexcr.2009.11.011

Peng, Y., Zhang, Y., and Zhou, J. (2010). p57Kip2 inhibits Tor treatment-induced cell proliferation, autophagy and cell death in prostate cancer cells. Exp. Cell Res. 316, 91–101. doi: 10.1016/j.yexcr.2009.11.011

Peng, Y., Zhang, Y., and Zhou, J. (2010). p57Kip2 inhibits Tor treatment-induced cell proliferation, autophagy and cell death in prostate cancer cells. Exp. Cell Res. 316, 91–101. doi: 10.1016/j.yexcr.2009.11.011

Peng, Y., Zhang, Y., and Zhou, J. (2010). p57Kip2 inhibits Tor treatment-induced cell proliferation, autophagy and cell death in prostate cancer cells. Exp. Cell Res. 316, 91–101. doi: 10.1016/j.yexcr.2009.11.011
inhibition of CDK1 activity. Genes Dev. 22, 3024–3036. doi: 10.1101/gad.171808
Urano, T., Yashiroda, H., Muraoka, M., Tanaka, K., Hosoi, T., Inoue, S., et al. (1999). p57(Kip2) is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor beta1. J. Biol. Chem. 274, 12197–12200. doi: 10.1074/jbc.274.18.12197
Vaccarella, G., Figliola, R., Cramerotti, S., Novelli, F., and Maione, R. (2006). Frontiers in Cell and Developmental Biology | www.frontiersin.org 15 October 2020 Volume 8 Article 584590

Yamazaki, S., Iwama, A., Takayanagi, S., Eto, K., Ema, H., and Nakauchi, H. (2009). Wierenga, A. T., Vellenga, E., and Schuringa, J. J. (2014). Convergence of hypoxia

Yin, Y., Zhang, F., Toma, S., Zhou, Y., Luo, J., Zhang, Y., et al. (2014). miR-29 promotes glioma cell proliferation by targeting CDKN1C. Biomed. Pharmacother. 71, 7–14. doi: 10.1016/j.biopha.2015.02.005

Zhang, M. C., Zhang, L., Zhang, M. Q., Yang, G. X., Wang, F. Z., and Ding, P. (2020). Downregulated LINC00628 aggravates the progression of colorectal cancer via inhibiting p57 level. Eur. Rev. Med. Pharmacol. Sci. 24, 1763–1770.

Zhang, P., Liegeois, N. J., Wong, C., Finegold, M., Hou, H., Thompson, J. C., et al. (2015). miR-25 promotes glioma cell proliferation by targeting CDKN1C. Biomed. Pharmacother. 71, 7–14. doi: 10.1016/j.biopha.2015.02.005

Zhang, M. C., Zhang, L., Zhang, M. Q., Yang, G. X., Wang, F. Z., and Ding, P. (2020). Downregulated LINC00628 aggravates the progression of colorectal cancer via inhibiting p57 level. Eur. Rev. Med. Pharmacol. Sci. 24, 1763–1770.

Zhang, P., Liegeois, N. J., Wong, C., Finegold, M., Hou, H., Thompson, J. C., et al. (2015). Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387, 151–158. doi: 10.1038/nature01510

Zhang, P., Wong, C., Depinho, R. A., Harper, J. W., and Elledge, S. J. (1998). Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57Kip2 requires binding to proliferating cell nuclear antigen. Proc. Natl. Acad. Sci. U.S.A. 95, 1392–1397. doi: 10.1073/pnas.95.4.1392

Westbury, J., Watkins, M., Ferguson-Smith, A. C., and Smith, J. (2001). Dynamic temporal and spatial regulation of the cdk inhibitor p57(kip2) during embryo morphogenesis. Mech. Dev. 109, 83–89. doi: 10.1016/s0925-4773(01)00512-3

Wierenga, A. T., Vellenga, E., and Schuringa, J. J. (2014). Convergence of hypoxia and TGFbeta pathways on cell cycle regulation in human hematopoietic stem/progenitor cells. PLoS One 9:e39349. doi: 10.1371/journal.pone.0039349

Yamazaki, S., Iwama, A., Takayanagi, S., Eto, K., Ema, H., and Nakauchi, H. (2009). TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 113, 1250–1256. doi: 10.1182/blood-2008-04-146480

Yan, Y., Frisen, J., Lee, M. H., Massague, J., and Barbacid, M. (1997). Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 11, 973–983. doi: 10.1101/gad.11.8.973

Yang, X., Karuturi, R. K., Sun, F., Aso, M., Yu, K., Shao, R., et al. (2009). Cdkn1C (p57) is a direct target of Ezh2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One 4:e5011. doi: 10.1371/journal.pone.0005011

Yokoo, T., Toyoshima, H., Miura, M., Wang, Y., Iida, K. T., Suzuki, H., et al. (2003). p57Kip2 regulates actin dynamics by binding and translocating LIM-kinase 1 to the nucleus. J. Biol. Chem. 278, 52919–52923. doi: 10.1074/jbc.m309334200

Yoon, M. K., Mitrea, D. M., Ou, L., and Kriwacki, R. W. (2012). Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem. Soc. Trans. 40, 981–988. doi: 10.1042/bst2011155

Zacharek, S. J., Fillmore, C. M., Lau, A. N., Gludish, D. W., Chou, A., Ho, J. W., et al. (2011). Lung stem cell self-renewal relies on BMI1-dependent control of expression at imprinted loci. Cell Stem Cell 9, 272–281. doi: 10.1016/j.stem.2011.07.007

Zalc, A., Hayashi, S., Aurade, F., Brohl, D., Chang, T., Mademtzoglou, D., et al. (2014). Antagonistic regulation of p57kip2 by Hes/Hey downstream of Notch signaling and muscle regulatory factors regulates skeletal muscle growth arrest. Development 141, 2780–2790. doi: 10.1242/dev.110155

Zhang, G., Xu, T., Wang, S., Gong, Z., Zou, C., Zhang, H., et al. (2019a). LncRNA SNHG17 promotes gastric cancer progression by epigenetically silencing of p15 and p57. J. Cell Physiol. 234, 5163–5174. doi: 10.1002/jcp.27320

Zhang, G., Xu, Y., Zou, C., Tang, Y., Lu, J., Gong, Z., et al. (2019b). Long noncoding RNA ARHGAP27P1 inhibits gastric cancer cell proliferation and cell cycle progression through epigenetically regulating p15 and p16. Aging 11, 9900–9110. doi: 10.18632/aging.102377

Zhang, J., Gong, X., Tian, K., Chen, D., Sun, J., Wang, G., et al. (2015). CREB3L1 promotes glioma cell proliferation by targeting CDKN1C. J. Biol. Chem. 280, 578–588. doi: 10.1074/jbc.M309334200

Zhang, J., Gong, X., Tian, K., Chen, D., Sun, J., Wang, G., et al. (2015). miR-25 promotes glioma cell proliferation by targeting CDKN1C. Biomed. Pharmacother. 71, 7–14. doi: 10.1016/j.biopha.2015.02.005

Zhang, M. C., Zhang, L., Zhang, M. Q., Yang, G. X., Wang, F. Z., and Ding, P. (2020). Downregulated LINC00628 aggravates the progression of colorectal cancer via inhibiting p57 level. Eur. Rev. Med. Pharmacol. Sci. 24, 1763–1770.

Zhang, P., Liegeois, N. J., Wong, C., Finegold, M., Hou, H., Thompson, J. C., et al. (1997). Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387, 151–158. doi: 10.1038/387151a0